FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1965633420> ?p ?o ?g. }

• W1965633420 endingPage "31661" @default.
• W1965633420 startingPage "31647" @default.
• W1965633420 abstract "Tissue factor pathway inhibitor-2 (TFPI-2) is a homologue of TFPI-1 and contains three Kunitz-type domains and a basic C terminus region. The N-terminal domain of TFPI-2 is the only inhibitory domain, and it inhibits plasma kallikrein, factor XIa, and plasmin. However, plasma TFPI-2 levels are negligible (≤20 pm) in the context of influencing clotting or fibrinolysis. Here, we report that platelets contain significant amounts of TFPI-2 derived from megakaryocytes. We employed RT-PCR, Western blotting, immunohistochemistry, and confocal microscopy to determine that platelets, MEG-01 megakaryoblastic cells, and bone marrow megakaryocytes contain TFPI-2. ELISA data reveal that TFPI-2 binds factor V (FV) and partially B-domain-deleted FV (FV-1033) with Kd ∼9 nm and binds FVa with Kd ∼100 nm. Steady state analysis of surface plasmon resonance data reveal that TFPI-2 and TFPI-1 bind FV-1033 with Kd ∼36–48 nm and bind FVa with Kd ∼252–456 nm. Further, TFPI-1 (but not TFPI-1161) competes with TFPI-2 in binding to FV. These data indicate that the C-terminal basic region of TFPI-2 is similar to that of TFPI-1 and plays a role in binding to the FV B-domain acidic region. Using pull-down assays and Western blots, we show that TFPI-2 is associated with platelet FV/FVa. TFPI-2 (∼7 nm) in plasma of women at the onset of labor is also, in part, associated with FV. Importantly, TFPI-2 in platelets and in plasma of pregnant women inhibits FXIa and tissue-type plasminogen activator-induced clot fibrinolysis. In conclusion, TFPI-2 in platelets from normal or pregnant subjects and in plasma from pregnant women binds FV/Va and regulates intrinsic coagulation and fibrinolysis. Tissue factor pathway inhibitor-2 (TFPI-2) is a homologue of TFPI-1 and contains three Kunitz-type domains and a basic C terminus region. The N-terminal domain of TFPI-2 is the only inhibitory domain, and it inhibits plasma kallikrein, factor XIa, and plasmin. However, plasma TFPI-2 levels are negligible (≤20 pm) in the context of influencing clotting or fibrinolysis. Here, we report that platelets contain significant amounts of TFPI-2 derived from megakaryocytes. We employed RT-PCR, Western blotting, immunohistochemistry, and confocal microscopy to determine that platelets, MEG-01 megakaryoblastic cells, and bone marrow megakaryocytes contain TFPI-2. ELISA data reveal that TFPI-2 binds factor V (FV) and partially B-domain-deleted FV (FV-1033) with Kd ∼9 nm and binds FVa with Kd ∼100 nm. Steady state analysis of surface plasmon resonance data reveal that TFPI-2 and TFPI-1 bind FV-1033 with Kd ∼36–48 nm and bind FVa with Kd ∼252–456 nm. Further, TFPI-1 (but not TFPI-1161) competes with TFPI-2 in binding to FV. These data indicate that the C-terminal basic region of TFPI-2 is similar to that of TFPI-1 and plays a role in binding to the FV B-domain acidic region. Using pull-down assays and Western blots, we show that TFPI-2 is associated with platelet FV/FVa. TFPI-2 (∼7 nm) in plasma of women at the onset of labor is also, in part, associated with FV. Importantly, TFPI-2 in platelets and in plasma of pregnant women inhibits FXIa and tissue-type plasminogen activator-induced clot fibrinolysis. In conclusion, TFPI-2 in platelets from normal or pregnant subjects and in plasma from pregnant women binds FV/Va and regulates intrinsic coagulation and fibrinolysis." @default.
• W1965633420 created "2016-06-24" @default.
• W1965633420 creator A5000263788 @default.
• W1965633420 creator A5001303264 @default.
• W1965633420 creator A5015452205 @default.
• W1965633420 creator A5022896212 @default.
• W1965633420 creator A5024565291 @default.
• W1965633420 creator A5038132884 @default.
• W1965633420 creator A5041562842 @default.
• W1965633420 creator A5049767878 @default.
• W1965633420 creator A5057634885 @default.
• W1965633420 creator A5064068211 @default.
• W1965633420 creator A5071883004 @default.
• W1965633420 date "2014-11-01" @default.
• W1965633420 modified "2023-10-18" @default.
• W1965633420 title "Platelets Contain Tissue Factor Pathway Inhibitor-2 Derived from Megakaryocytes and Inhibits Fibrinolysis" @default.
• W1965633420 cites W1565241971 @default.
• W1965633420 cites W1811239707 @default.
• W1965633420 cites W1919627560 @default.
• W1965633420 cites W1949259756 @default.
• W1965633420 cites W1967322305 @default.
• W1965633420 cites W1981417802 @default.
• W1965633420 cites W1983807300 @default.
• W1965633420 cites W1984958828 @default.
• W1965633420 cites W1986703727 @default.
• W1965633420 cites W1988267589 @default.
• W1965633420 cites W1991481331 @default.
• W1965633420 cites W1992763777 @default.
• W1965633420 cites W2002180158 @default.
• W1965633420 cites W2008211081 @default.
• W1965633420 cites W2011089116 @default.
• W1965633420 cites W2011126954 @default.
• W1965633420 cites W2011784685 @default.
• W1965633420 cites W2013306997 @default.
• W1965633420 cites W2013951540 @default.
• W1965633420 cites W2019908848 @default.
• W1965633420 cites W2020185126 @default.
• W1965633420 cites W2021355386 @default.
• W1965633420 cites W2025560812 @default.
• W1965633420 cites W2026740600 @default.
• W1965633420 cites W2029974398 @default.
• W1965633420 cites W2031311872 @default.
• W1965633420 cites W2032505028 @default.
• W1965633420 cites W2032804123 @default.
• W1965633420 cites W2035926017 @default.
• W1965633420 cites W2037257561 @default.
• W1965633420 cites W2040465501 @default.
• W1965633420 cites W2042314261 @default.
• W1965633420 cites W2047110468 @default.
• W1965633420 cites W2054139674 @default.
• W1965633420 cites W2060279467 @default.
• W1965633420 cites W2062110544 @default.
• W1965633420 cites W2070396494 @default.
• W1965633420 cites W2071508156 @default.
• W1965633420 cites W2072235390 @default.
• W1965633420 cites W2074449688 @default.
• W1965633420 cites W2077365176 @default.
• W1965633420 cites W2077925351 @default.
• W1965633420 cites W2079132877 @default.
• W1965633420 cites W2079709555 @default.
• W1965633420 cites W2080786556 @default.
• W1965633420 cites W2082906800 @default.
• W1965633420 cites W2083431276 @default.
• W1965633420 cites W2084483224 @default.
• W1965633420 cites W2085397246 @default.
• W1965633420 cites W2087077722 @default.
• W1965633420 cites W2091629675 @default.
• W1965633420 cites W2091770999 @default.
• W1965633420 cites W2094070957 @default.
• W1965633420 cites W2095462890 @default.
• W1965633420 cites W2095715212 @default.
• W1965633420 cites W2099092415 @default.
• W1965633420 cites W2100837269 @default.
• W1965633420 cites W2106046020 @default.
• W1965633420 cites W2107218017 @default.
• W1965633420 cites W2108909942 @default.
• W1965633420 cites W2109846135 @default.
• W1965633420 cites W2110729573 @default.
• W1965633420 cites W2113285433 @default.
• W1965633420 cites W2123294765 @default.
• W1965633420 cites W2129377727 @default.
• W1965633420 cites W2148693904 @default.
• W1965633420 cites W2151605451 @default.
• W1965633420 cites W2152710818 @default.
• W1965633420 cites W2156686805 @default.
• W1965633420 cites W2159629485 @default.
• W1965633420 cites W2170028461 @default.
• W1965633420 cites W2317820864 @default.
• W1965633420 cites W2414243582 @default.
• W1965633420 cites W2577055267 @default.
• W1965633420 cites W4235065778 @default.
• W1965633420 cites W4379250858 @default.
• W1965633420 cites W45091422 @default.
• W1965633420 doi "https://doi.org/10.1074/jbc.m114.569665" @default.
• W1965633420 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4223360" @default.
• W1965633420 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25262870" @default.
• W1965633420 hasPublicationYear "2014" @default.
• W1965633420 type Work @default.

• next